hazard and risk management
DESCRIPTION
Hazard and Risk Management. E. Stewart Geary, M.D. Eisai Co., Ltd. National Regulatory Conference 2005 Subang Jaya, Selangor, Malaysia 6-7 September, 2005. Hazard & Risk Management. Principles of Risk Management Risk Management: Clinical Safety of Medical Products ICH: E2E Guideline EU - PowerPoint PPT PresentationTRANSCRIPT
Hazard and Risk Management
E. Stewart Geary, M.D.
Eisai Co., Ltd.
National Regulatory Conference 2005
Subang Jaya, Selangor, Malaysia
6-7 September, 2005
Risk Management National Regulatory Conference 2005
2
Hazard & Risk Management
• Principles of Risk Management
• Risk Management: Clinical Safety of Medical Products– ICH: E2E Guideline– EU– FDA: 3 Guidances
Risk Management National Regulatory Conference 2005
4
Risk
• “Risk can be defined as the combination of the probability of an event and its consequences” (ISO/IEC Guide 73)
Risk Management National Regulatory Conference 2005
5
Risk Management
• Process by which organizations methodically address the risks associated with their activities
• Requires identification and “treatment” of risks• Should be a continuous and developing process• Management of safety risks focuses on prevention
and mitigation of harm
Risk Management National Regulatory Conference 2005
6
Types of Risks: External
• Financial risks– Interest rates– Foreign exchange
• Strategic Risks– Competition– Industry changes
• Operational Risks– Regulations
• Hazard Risks– Natural disasters– Contracts– Suppliers
Risk Management National Regulatory Conference 2005
7
Types of Risks: Internal
• Financial risks– Liquidity & Cash Flow
• Strategic Risks– Research & Development– Intellectual capital
• Operational Risks– Accounting controls– Information systems
• Hazard Risks– Employees– Properties
Risk Management National Regulatory Conference 2005
8
Risk Management
• Cycle of Management– Risk Identification
– Risk Assessment
– Plan
– Implement Risk Treatment
– Assess the implemented plan
• Report internally and externally on the identified risk and the progress of its management
Risk Management National Regulatory Conference 2005
9
Mitigate/Treat
Identify Assess/Analyze
Plan
Risk Management Cycle
Tra
ck
ReportReport
Risk Management National Regulatory Conference 2005
11
Background: E2E• E2E: Pharmacovigilance Plans
– The Guideline was released for consultation, under Step 2 of the ICH process, on November 11, 2003.
– EU : Adopted by CPMP, 20 November 2003, issued as CPMP/ICH/5716/03
– MHLW : Released for consultation on April 27, 2004, PFSB/ELD, Deadline for comments July 26, 2004
– FDA : Published in the Federal Register, Vol. 69, No 61, Tuesday, March 30, 2004, pages 16579-80.Comments due by May 19, 2004.
Risk Management National Regulatory Conference 2005
12
Background EU
• “Action Plan to Further Progress the European Risk Management Strategy” published 4 May 2005– Risk Detection– Risk Assessment– Risk Minimization– Risk Communication
Risk Management National Regulatory Conference 2005
13
Background: RiskMAP• PDUFA III approval June, 2002 included FDA promise
to produce guidance for industry on risk management• 3 Concept Papers issued March 2003
– Public Workshop April 2003
• 3 Draft Guidance Documents issued May, 2004– Development and Use of Risk Minimization Action Plans– Good Pharmacovigilance Practices and
Pharmacoepidemiologic Assessment• Includes guidance on when to develop PVP
– Premarketing Risk Assessment
• 3 Guidances Finalized March 2005
Risk Management National Regulatory Conference 2005
15
E2E
• Pharmacovigilance Specification– Summary of the identified risks of the drug– Potential for important unidentified risks– Populations potentially at-risk– Situations that have not been adequately
studied
• Pharmacovigilance Plan
• Annex of Pharmacovigilance Methods
Risk Management National Regulatory Conference 2005
16
Pharmacovigilance Specification
• Summary of the identified risks of the drug
• Potential for important unidentified risks
• Populations potentially at-risk
• Situations that have not been adequately studied
• Can be stand-alone or incorporated in CTD
Risk Management National Regulatory Conference 2005
17
Elements of PV Specification
• Non-clinical• Clinical
– Limitations of human safety database• Extent of world-wide exposure• Any new or different safety issues identified• Regulatory actions related to safety
– Populations not studied in pre-approval phase• Children, elderly, pregnancy & lactation, hepatic or
renal disease, genetic polymorphisms, ethnic origin
Risk Management National Regulatory Conference 2005
18
Elements of PV Specification
• Clinical– AE/ADR
• Most important identified ADRs (by frequency or seriousness)
• Potential risks (how will they be further identified?)
– Food-drug and drug-drug interactions– Epidemiology of indication and associated AEs– Class effects
• Summary - Ongoing safety issues
Risk Management National Regulatory Conference 2005
19
PV Plan
• Summary of Ongoing Safety Issues– Important identified risks– Important potential risks– Important missing information
• Routine PV Practices• Safety Action Plan for specific
issues/missing information• Summary of actions to be done, milestones
Risk Management National Regulatory Conference 2005
20
Safety Action Plan for specific issues/missing information
• Risk Issue/Information missing• Objective• Action proposed• Rationale for proposed action• Oversight within company for issue & action• Milestones for evaluation and reporting
– Exposure to product reaching certain levels
– Results of studies becoming available
Risk Management National Regulatory Conference 2005
21
E2E-Safety Action Plan
• Safety Action Plan– The objective is to have a more structured and
specific approach to examining pre-defined safety issues
• Is the product safe for elderly patients?
• Is there a risk for cardiac events? How great is that risk?
– Analyses to be performed at each milestone
Risk Management National Regulatory Conference 2005
22
E2E-Safety Action Plan
• If a Safety Action Plan results in specific actions there is a need to follow-up and see if those actions improved the risk profile– For instance: Did a Package insert change or
specific education program result in a decrease in the adverse event of concern?
Risk Management National Regulatory Conference 2005
23
Summary: E2E-Safety Action Plan
• Created on the basis of conscious assessment of current safety information
• Targeted plan to address a specific question– Usually involves gathering more information to better
define a specific risk
• Requires re-assessment and modification at pre-determined milestones
• Submitted to a regulatory authority for comment and approval
Risk Management National Regulatory Conference 2005
26
Premarketing Risk Assessment• Depends on
– Quantity of patients studied– Quality of data analysis
• Size of database– Smaller for life-threatening diseases– Difficult to offer guidance for products used for short-term, a
cute use– Long-term treatment of non-life-threatening Dz (E1A)
• 1500 patients exposed of which• 300-600 for 6 months• 100 for 1 year• Reasonable exposure to highest proposed dose
Risk Management National Regulatory Conference 2005
27
Premarketing Risk Assessment
• Larger databases needed for– Safety concern from animal studies,
pharmacological class, etc.– Small benefit– Preventive therapies (few of exposed benefit)– Uncertain magnitude of benefit– Use in healthy population– Safe and effective alternative already available
Risk Management National Regulatory Conference 2005
28
Premarketing Risk Assessment• Examine terminology, assessment methods, use of
standard terms– MedDRA
• Consider long-term controlled studies– Most extensions are single-arm or otherwise uncontrolled– For comparison group for evaluation of events common
in that background population
• Diverse population in safety database– Old, young, women, minorities, limit exclusion criteria
• Multiple doses in phase III
Risk Management National Regulatory Conference 2005
29
Premarketing Risk Assessment• Detecting Unanticipated Interactions
– Drug-drug interactions in addition to those predicted by metabolic pathway
• For likely concomitant medications used in that population
– Product-dietary supplement interactions
• Comparative Safety Data– Especially when background rate of AEs is
high or other drugs in class have same ADRs
Risk Management National Regulatory Conference 2005
30
Premarketing Risk Assessment: Data Analysis
• Essentially the same tools currently used for the Integrated Safety Summary
• Similar to E2E “PV Specification”
Risk Management National Regulatory Conference 2005
32
Role of RiskMAPs
• Necessary for only some products– “For most products routine risk management
will be sufficient and a RiskMAP need not be considered.”
• RiskMAP: a strategic safety program designed to meet specific goals and objectives in minimizing known risks while preserving benefits
Risk Management National Regulatory Conference 2005
33
RiskMAP
• State a specific goal– “fetal exposure to drug X should not occur”– “lower incidence of liver failure on drug X”
• Translate into pragmatic, specific and measurable objectives– Targeted education to physicians, patients– Reminder systems– Access systems
Risk Management National Regulatory Conference 2005
34
RiskMAP Tools
• Targeted education & outreach– Health care practitioner letters– Training programs– Continuing education– Professional/public notifications– Medication guides– Patient package inserts– Focused or limited promotion techniques
Risk Management National Regulatory Conference 2005
35
RiskMAP Tools
• Reminder systems– Patient agreement forms– Certification programs for practitioners– Limit amount in single prescription– Specialized product packaging– Systems to attest safety measures are satisfied
(stickers, etc.)
Risk Management National Regulatory Conference 2005
36
RiskMAP Tools
• Performance-linked access systems– Link product access to lab test results or other
documentation– Compulsory reminder systems (no product
without acknowledgment)– Prescription only by specified practitioners– Dispensing only by specially certified
pharmacies
Risk Management National Regulatory Conference 2005
37
FDA’s Tools
• Product recalls
• Warning letters
• Safety alerts
• Guidance documents
• Seizures and injunctions
Risk Management National Regulatory Conference 2005
38
RiskMAP
• Every RiskMAP should contain a plan to periodically evaluate its effectiveness– Test tools before implementation if possible (e.g.
during phase III)– RiskMAP plan should describe when periodic
evaluation results will be sent to FDA– Eliminate ineffective tools
• RiskMAP evaluations will involve analysis of observational/descriptive data rather than statistical hypothesis testing
Risk Management National Regulatory Conference 2005
39
RiskMAP
• Select evidence-based performance measures– Number, percentage or rate of an outcome– Whenever possible use at least two different
measures/methods for each goal
• Submit RiskMAP to IND/NDA/BLA
Risk Management National Regulatory Conference 2005
40
RiskMAP Contents
• Background
• Goals & Objectives
• Strategy & Tools
• Evaluation Plan– Including potential unintended and untoward
consequences of the RiskMAP
Risk Management National Regulatory Conference 2005
41
RiskMAP Progress Report
• Summary of the RiskMAP
• Methodology
• Data
• Results
• Discussion & Conclusions
Risk Management National Regulatory Conference 2005
42
RiskMAP Data Analysis• Emphasis is on selecting a quantitative “performance
measure”– Number, percentage or rate of outcome
• Careful consideration at the time of choosing a performance measure– Adapting to increasing exposure to drug as use expands– New population exposures as new indications or new countries get
marketing approval
• Data analysis to demonstrate the performance measure is being met
• If performance measure is not met, need to consider new actions/additions to RiskMAP
Risk Management National Regulatory Conference 2005
43
Summary: Safety Action Plan vs RiskMAP
• Broadly defined, all products have always had a PVP– Package insert, CCDS, ADR collection & reporting
• Some but not all products will require a PVP Safety Action Plan or RiskMAP
• FDA’s RiskMAP is similar to the Safety Action Plan in E2E but is targeted to reduce a specific risk
Risk Management National Regulatory Conference 2005
44
Summary: Safety Action Plan vs RiskMAP
• Both PVP and RiskMAP’s are marked by– Moving from a reactive to proactive model of PV– Moving from “one size fits all” PV to tailored programs specific
for each drug– Setting measurable targets for drug safety and periodically
assessing whether or not they have been met
• RiskMAP takes a specific risk and creates a plan to minimize it
• Pharmacovigilance Plan gathers more information to identify risks